 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 93,9% |
| Metabolism | Liver (mainlyCYP3A4) |
| Eliminationhalf-life | 7.3–12.1 hours |
| Excretion | Biliary |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H36N6O4S |
| Molar mass | 516.66 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
The drugudenafil is marketed under the trade nameZydena. It is within thePDE5 inhibitor class (which also includesavanafil,sildenafil,tadalafil, andvardenafil). Like other PDE5 inhibitors, it is used to treaterectile dysfunction. Udenafil was developed by Dong-A Pharmaceutical.[1] It has fairly rapid onset of action (peakplasma concentration after 1 to 1.5 hours), and has long duration of action (plasmahalf-life of 11 to 13 hours). Udenafil'spharmacokinetics allows once-daily dosage (in addition to on-demand use).[2] Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines.[3] It has not yet been approved for use in the United States by theU.S. Food and Drug Administration.
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
